---
title: Amgen Inc. AMGN
description: |
    Amgen is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics worldwide, focusing on serious illnesses with significant unmet medical needs.
sidebar:
    label: Amgen AMGN
    order: 457
unsplash: 1559757148-7d4e0223ce8c
img: https://images.unsplash.com/photo-1559757148-7d4e0223ce8c?fit=crop&w=1400&h=700&q=75
tags:
  - stock
  - biotechnology
  - pharmaceuticals
  - amgn
  - healthcare
---

import TradingView from '@/components/charts/TradingView.astro';

import {
  Aside,
  Steps,
  Card,
  CardGrid,
  Code,
  FileTree,
} from '@astrojs/starlight/components';

import { Giscus, Adsense } from '@/components/astropad';

<TradingView data={`nasdaq:amgn`} />

<Adsense />

<Aside title="Not Financial Advice" type="danger">
This is not financial advice. The data compiled here is for easier referencing purposes only and may not be accurate. Always consult with a qualified financial advisor before making any investment decisions.
</Aside>

## AMGN - Biotechnology Innovation Leader

Amgen Inc. (NASDAQ: AMGN) is one of the world's leading biotechnology companies, pioneering the discovery, development, manufacturing, and delivery of innovative human therapeutics for serious illnesses with significant unmet medical needs. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen has established itself as a biotechnology pioneer, creating life-saving medicines through advanced science and cutting-edge manufacturing capabilities.

With a market capitalization exceeding $155 billion and approximately 28,000 employees worldwide, Amgen operates across multiple therapeutic areas including oncology, cardiovascular disease, inflammation, bone health, and nephrology. The company's robust pipeline, strong commercial portfolio, and innovative manufacturing platforms position it as a leader in the rapidly evolving biotechnology landscape.

## Comprehensive Therapeutic Portfolio

Amgen's extensive product portfolio addresses critical medical needs across multiple therapeutic areas:

### Oncology and Hematology
Leading cancer treatments and blood disorder therapies:

- **LUMAKRAS/LUMYKRAS**: First-in-class KRAS G12C inhibitor for non-small cell lung cancer
- **BLINCYTO**: Bispecific T-cell engager for acute lymphoblastic leukemia
- **KYPROLIS**: Proteasome inhibitor for relapsed or refractory multiple myeloma
- **Vectibix**: EGFR antagonist for metastatic colorectal cancer
- **XGEVA**: RANKL inhibitor for skeletal-related events prevention
- **IMDELLTRA**: Novel therapy showing significant survival benefits in small cell lung cancer
- **Nplate**: Thrombopoietin receptor agonist for immune thrombocytopenia

### Cardiovascular Disease
Innovative treatments for cardiovascular risk reduction:

- **Repatha**: PCSK9 inhibitor reducing cardiovascular events and lowering LDL cholesterol
- **EVENITY**: Sclerostin inhibitor for osteoporosis treatment
- **Cardiovascular Pipeline**: Advanced therapies targeting lipid disorders and cardiovascular protection

### Inflammation and Immunology
Treatments for inflammatory and autoimmune conditions:

- **Enbrel**: TNF blocker for rheumatoid arthritis, psoriasis, and psoriatic arthritis
- **Otezla**: PDE4 inhibitor for psoriasis, psoriatic arthritis, and Beh√ßet's disease
- **TEPEZZA**: Breakthrough therapy for thyroid eye disease
- **TEZSPIRE**: Biologic for severe asthma (in collaboration with AstraZeneca)

### Bone Health and Nephrology
Specialized treatments for bone disorders and kidney disease:

- **Prolia**: RANKL inhibitor for osteoporosis in postmenopausal women
- **PARSABIV**: Calcimimetic for secondary hyperparathyroidism
- **Sensipar**: Calcium-sensing receptor agonist for chronic kidney disease
- **EPOGEN**: Erythropoiesis-stimulating agent for anemia

## Innovation and Research Excellence

<CardGrid>
  <Card title="Pipeline Strength" icon="flask">
    Robust pipeline with multiple late-stage assets across therapeutic areas
  </Card>
  <Card title="Biologic Expertise" icon="dna">
    Leading expertise in protein engineering and biologic drug development
  </Card>
  <Card title="Manufacturing Excellence" icon="factory">
    State-of-the-art biomanufacturing capabilities ensuring quality and scale
  </Card>
  <Card title="Clinical Research" icon="stethoscope">
    Comprehensive clinical development programs and real-world evidence generation
  </Card>
  <Card title="Technology Platforms" icon="cpu">
    Advanced technology platforms including BiTE, XGEVA, and multispecific antibodies
  </Card>
  <Card title="Strategic Partnerships" icon="handshake">
    Collaborative partnerships expanding development capabilities and market reach
  </Card>
</CardGrid>

## Financial Performance

### Strong Operating Metrics
- **Market Cap**: ~$155.74 billion
- **Revenue**: $34.13 billion (trailing twelve months)
- **Net Income**: $5.93 billion
- **Profit Margin**: 17.39%
- **Free Cash Flow**: $13.09 billion

### Financial Health Indicators
- **Dividend Yield**: 3.29% with consistent quarterly payments
- **Return on Equity**: 105.67% (reflecting efficient capital utilization)
- **Cash Position**: $8.81 billion supporting R&D and strategic investments
- **R&D Investment**: Substantial research and development spending driving innovation
- **Patent Protection**: Strong intellectual property portfolio protecting key products

## Research and Development Pipeline

### Late-Stage Development Programs
Amgen maintains a robust pipeline with multiple potential blockbuster therapies:

- **Maritide (AMG 133)**: GLP-1/GIP dual receptor agonist for obesity and diabetes showing promising Phase 2 results
- **Rocatinlimab**: Anti-OX40 antibody for atopic dermatitis and other inflammatory conditions
- **AMG 510 (LUMAKRAS) Expansion**: Additional indications for KRAS G12C inhibitor
- **Tarlatamab**: DLL3-targeted BiTE for small cell lung cancer
- **AMG 193**: BACE1 inhibitor for Alzheimer's disease prevention

### Technology Platforms and Innovation
- **BiTE Technology**: Bispecific T-cell engager platform creating novel cancer immunotherapies
- **Multispecific Antibodies**: Next-generation antibody platforms targeting multiple pathways
- **Protein Engineering**: Advanced protein design and optimization capabilities
- **Gene Editing**: CRISPR and other gene editing technologies for therapeutic development
- **Digital Health**: Digital therapeutics and connected health solutions

## Investment Considerations

### Growth Drivers
- **Pipeline Advancement**: Multiple late-stage assets with blockbuster potential entering the market
- **Obesity Market**: Maritide positioning Amgen in the rapidly growing obesity therapeutics market
- **Oncology Expansion**: LUMAKRAS and other oncology assets expanding into additional indications
- **International Growth**: Geographic expansion and international market penetration
- **Biosimilar Defense**: New products and indications offsetting biosimilar competition
- **Manufacturing Excellence**: Advanced manufacturing capabilities supporting growth and margins

### Competitive Advantages
- **Scientific Leadership**: Pioneering biotechnology research and development capabilities
- **Manufacturing Scale**: World-class biomanufacturing network ensuring quality and efficiency
- **Regulatory Expertise**: Deep regulatory knowledge and successful approval track record
- **Commercial Excellence**: Strong commercial organization and global market access
- **Financial Resources**: Substantial cash generation funding continued innovation
- **Talent and Culture**: Attracting top scientific and commercial talent globally

### Risk Factors
- **Patent Expiration**: Loss of exclusivity for key products to biosimilar competition
- **Clinical Trial Risk**: Potential failure of pipeline assets in clinical development
- **Regulatory Risk**: Regulatory approval delays or rejections affecting product launches
- **Competition**: Intense competition from other biotechnology and pharmaceutical companies
- **Pricing Pressure**: Healthcare cost containment affecting product pricing and reimbursement
- **Manufacturing Risk**: Complex biomanufacturing processes subject to operational challenges
- **Economic Sensitivity**: Healthcare spending sensitivity to economic downturns

## Manufacturing and Quality Excellence

### Advanced Biomanufacturing
Amgen operates one of the world's most sophisticated biomanufacturing networks:

- **Puerto Rico Operations**: Large-scale biologics manufacturing facility
- **Rhode Island Facility**: State-of-the-art drug substance manufacturing
- **Ohio Expansion**: $900 million manufacturing expansion creating 350 new jobs
- **Global Network**: Manufacturing facilities across multiple continents
- **Quality Systems**: Comprehensive quality assurance and regulatory compliance
- **Capacity Planning**: Strategic capacity investments supporting pipeline growth

### Technology and Innovation
- **Process Development**: Advanced bioprocess development and optimization
- **Digital Manufacturing**: Industry 4.0 technologies and data analytics
- **Automation**: Robotic process automation and advanced manufacturing systems
- **Sustainability**: Environmental sustainability and green manufacturing initiatives

## Strategic Partnerships and Collaborations

### Key Partnerships
Amgen leverages strategic partnerships to enhance development capabilities:

- **AstraZeneca**: TEZSPIRE development and commercialization for severe asthma
- **Novartis**: Aimovig development and commercialization for migraine prevention
- **UCB**: EVENITY development and commercialization for osteoporosis
- **Kyowa Kirin**: Rocatinlimab development and commercialization
- **BeiGene**: Oncology products expansion and development in China

### Academic and Research Collaborations
- **University Partnerships**: Collaborative research with leading academic institutions
- **Research Consortiums**: Participation in industry research initiatives
- **Innovation Labs**: External innovation partnerships and venture investments

## ESG Leadership and Corporate Responsibility

<CardGrid>
  <Card title="Patient Access" icon="users">
    Comprehensive patient access programs and affordability initiatives
  </Card>
  <Card title="Environmental Stewardship" icon="leaf">
    Sustainability initiatives and environmental impact reduction
  </Card>
  <Card title="Workforce Development" icon="graduation-cap">
    Employee development and STEM education programs
  </Card>
  <Card title="Community Impact" icon="building-community">
    Global health initiatives and community investment programs
  </Card>
</CardGrid>

### Environmental Leadership
- **Carbon Neutrality**: Commitment to carbon neutrality and renewable energy adoption
- **Sustainable Manufacturing**: Green chemistry and sustainable manufacturing practices
- **Water Conservation**: Water conservation and environmental protection programs
- **Waste Reduction**: Comprehensive waste reduction and recycling initiatives

### Social Impact
- **Patient Assistance**: Extensive patient assistance programs ensuring medication access
- **Global Health**: Initiatives addressing global health challenges and healthcare access
- **STEM Education**: Science education programs inspiring the next generation of innovators
- **Diversity and Inclusion**: Comprehensive diversity and inclusion programs and metrics

## Global Operations and Market Access

### Geographic Presence
Amgen operates across major pharmaceutical markets worldwide:

- **United States**: Largest market with comprehensive commercial operations
- **Europe**: Significant presence across European Union markets
- **Asia Pacific**: Growing operations in Japan, Australia, and emerging markets
- **Emerging Markets**: Strategic expansion in Latin America and other developing regions

### Market Access and Reimbursement
- **Payer Relationships**: Strong relationships with health insurance payers and government programs
- **Health Economics**: Comprehensive health economics and outcomes research
- **Value-Based Care**: Innovative pricing and contracting models
- **Patient Support**: Comprehensive patient support programs and co-pay assistance

## Future Growth Opportunities

### Emerging Therapeutic Areas
- **Obesity and Diabetes**: Maritide and future incretin-based therapies
- **Neurodegeneration**: Alzheimer's disease and other neurodegenerative conditions
- **Autoimmune Diseases**: Novel approaches to inflammatory and autoimmune conditions
- **Cancer Immunotherapy**: Next-generation cancer immunotherapies and combination approaches

### Technology Integration
- **Digital Health**: Digital therapeutics and remote patient monitoring
- **Artificial Intelligence**: AI-driven drug discovery and development
- **Precision Medicine**: Genomics-guided therapy selection and personalized medicine
- **Cell and Gene Therapy**: Advanced cell and gene therapy platforms

## Investment Outlook

### Value Proposition
AMGN offers exposure to biotechnology innovation with established commercial success:

- **Diversified Portfolio**: Balanced portfolio of established products and promising pipeline
- **Innovation Leadership**: Proven track record of bringing breakthrough therapies to market
- **Financial Strength**: Strong cash generation supporting continued R&D investment
- **Dividend Income**: Attractive dividend yield with consistent payment history

### Key Metrics to Monitor
- **Pipeline Progress**: Clinical trial results and regulatory approval timelines
- **Product Performance**: Sales growth of key products including LUMAKRAS and new launches
- **Maritide Development**: Progress of obesity therapy through clinical development
- **Biosimilar Impact**: Market share retention in the face of biosimilar competition
- **R&D Productivity**: Return on R&D investment and pipeline advancement
- **International Expansion**: Growth in international markets and emerging economies

<Giscus />
